Trial Profile
A Double-Blind, Vehicle-Controlled, Rising Dose, Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary) ; Betamethasone dipropionate; Calcipotriol
- Indications Plaque psoriasis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Incyte Corporation
- 21 Jun 2010 Actual end date change from Jan 2009 to Apr 2009 as reported by ClinicalTrials.gov.
- 14 Oct 2009 New trial record.